<?xml version='1.0' encoding='utf-8'?>
<document id="26365907"><sentence text="A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort."><entity charOffset="100-110" id="DDI-PubMed.26365907.s1.e0" text="everolimus" /></sentence><sentence text="JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4)" /><sentence text=" None of the currently approved angiogenesis inhibitors have been reported to inhibit EphB4, and therefore, JI-101 has a novel mechanism of action" /><sentence text=" We conducted a pilot trial to assess the pharmacokinetics (PK), tolerability, and efficacy of JI-101 in combination with everolimus in advanced cancers, and pharmacodynamics (PD), tolerability, and efficacy of JI-101 in ovarian cancer"><entity charOffset="122-132" id="DDI-PubMed.26365907.s4.e0" text="everolimus" /></sentence><sentence text=" This was the first clinical study assessing anti-tumor activity of JI-101 in a combinatorial regimen" /><sentence text=" In the PK cohort, four patients received single agent 10 mg everolimus on day 1, 10 mg everolimus and 200 mg JI-101 combination on day 8, and single agent 200 mg JI-101 on day 15"><entity charOffset="61-71" id="DDI-PubMed.26365907.s6.e0" text="everolimus" /><entity charOffset="88-98" id="DDI-PubMed.26365907.s6.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.26365907.s6.e0" e2="DDI-PubMed.26365907.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26365907.s6.e0" e2="DDI-PubMed.26365907.s6.e1" /></sentence><sentence text=" In the PD cohort, eleven patients received single agent JI-101 at 200 mg twice daily for 28 day treatment cycles" /><sentence text=" JI-101 was well tolerated as a single agent and in combination with everolimus"><entity charOffset="69-79" id="DDI-PubMed.26365907.s8.e0" text="everolimus" /></sentence><sentence text=" No serious adverse events were observed" /><sentence text=" Common adverse events were hypertension, nausea, and abdominal pain" /><sentence text=" JI-101 increased exposure of everolimus by approximately 22%, suggestive of drug-drug interaction"><entity charOffset="30-40" id="DDI-PubMed.26365907.s11.e0" text="everolimus" /></sentence><sentence text=" The majority of patients had stable disease at their first set of restaging scans (two months), although no patients demonstrated a response to the drug per RECIST criteria" /><sentence text=" The novel mechanism of action of JI-101 is promising in ovarian cancer treatment and further prospective studies of this agent may be pursued in a less refractory patient population or in combination with cytotoxic chemotherapy" /><sentence text="" /></document>